Perbandingan Gambaran Histopatologi Lambung Tikus Wistar Setelah Pemberian Deksketoprofen dan Ketorolak

*Taufik Eko Nugroho -  Bagian Anestesiologi dan Terapi Intensif, Fakultas Kedokteran, Universitas Diponegoro/ RSUP Dr. Kariadi Semarang, Indonesia
Datu Abdul Rahman Hakim -  Bagian Anestesiologi dan Terapi Intensif, Fakultas Kedokteran, Universitas Diponegoro/ RSUP Dr. Kariadi Semarang, Indonesia
Hari Hendriarto Satoto -  Bagian Anestesiologi dan Terapi Intensif, Fakultas Kedokteran, Universitas Diponegoro/ RSUP Dr. Kariadi Semarang, Indonesia
Published: 1 Mar 2019.
Open Access
Citation Format:
Article Info
Section: Penelitian
Language: ID
Full Text:
Supp. File(s):
Copyright Transfer Agreement
Subject
Type Other
  View (1MB)    Indexing metadata
Statistics: 329 432
Abstract

Latar Belakang: Obat anti inflamasi nonsteroid (OAINS) merupakan obat yang memiliki kemampuan untuk mengatasi nyeri, sehingga dapat digunakan untuk pengelolaan nyeri pasca bedah. Ketorolak dan deksketoprofen merupakan OAINS bekerja dengan cara menghambat aktifitas enzim siklooksigenase (COX) baik enzim siklooksigenase-1 (COX-1) maupun enzim siklooksigenase-2 (COX-2) sehingga sintesis dari prostaglandin (PG) juga terhambat. PG khususnya Prostlagandin E2 (PGE2) sebenarnya merupakan zat yang bersifat protektor untuk mukosa saluran cerna atas. Hambatan sintesis PG akan mengurangi ketahanan mukosa, dengan efek berupa lesi akut mukosa lambung bentuk ringan sampai berat.10

Tujuan: Mengetahui perbedaan gambaran histopatologi lambung tikus wistar setelah pemberian deksketoprofen dan ketorolak.

Metode: Dilakukan penelitian eksperimental laboratorik menggunakan randomized post test control group design pada 14 ekor tikus wistar jantan yang dibagi menjadi 2 kelompok secara acak masing- masing kelompok terdiri dari 7 ekor tikus wistar yang diberi luka incisi. Kelompok I mendapat deksketoprofen 0,9 mg intramuskular tiap 8 jam selama 5 hari dan Kelompok II mendapat ketorolak dengan dosis 0,54mg intramuskuler tiap 8 jam selama 5 hari. Setelah itu dilakukan terminasi serta pengambilan jaringan lambung dan dianalisis gambaran histopatologinya. Uji statistik normalitas data dengan menggunakan Saphiro wilk, uji beda dengan menggunakan Independent T Test.

Hasil: Dari hasil uji Independent T Test didapatkan nilai p antara kelompok I terhadap kelompok II P = 0,029 sehingga terdapat perbedaan yang bermakna antara kelompok I dan kelompok II

Kesimpulan: Terdapat perubahan gambaran histopatologis lambung tikus wistar setelah pemberian deksketoprofen dan ketorolak, dimana perubahan gambaran histopatologi lambung tikus wistar pada pemberian deksketoprofen lebih sedikit dibandingkan dengan ketorolak.

Note: This article has supplementary file(s).

Keywords
cox; deksketoprofen; gambaran histopatologi lambung; ketorolac; OAINS

Article Metrics:

  1. Prayogi K. Perbandingan nilai visual analogue scale dan efek samping dari gabapentin 900 mg dengan gabapentin 1200 mg per oral sebagai preemptif analgesia pascabedah dengan spinal anestesi. J Anesthesiol. 2015.
  2. Meliala L PR. Breakthrough in management of acute pain. DEXAMEDIA. 2007;4(20):151-155.
  3. Stoelting RK HS. Opioid Agonists and Antagonists, Local Anesthetics, Cyclooxygenase-2 Inhibitor and Nonspecific Nonsteroidal In: Pharmacology & Physiology in Anesthetic Practice Antiinflammatory Drugs. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2006.
  4. Gosal F, Paringkoan B WN. Patofisiologi dan penanganan gastropati obat antiinflamasi nonsteroid. J Indon Med Assoc. 2012;62(11):444-449.
  5. Manan C. Gastropati obat antiinflamasi nonsteroid. In: Rani AA, Manan C, Djojoningrat D, Simadibrata MK, Makmun D AM, ed. Dispepsia Sains Dan Aplikasi Klinik. Jakarta: Pusat Penerbitan Departemen IPD FKUI; 2005:68-76.
  6. Tortora, GJ, Derrickson B. The Digestive System. In: Principles Of Anatomy and Physiology. 12th ed. USA: John Wiley&Sons, Inc; 2009.
  7. Sarjadi. Patologi Umum. Semarang: Badan Penerbit Universitas Diponegoro; 2003.
  8. Gray H. Anatomy of the Human Body. 30th ed. Philadelphia: Lea and Febiger; 1986.
  9. Schlansky B HJ. Prevention of nonsteroidal anti inflammatory drug induced gastropathy. Gastroenterol. 2009;44(19):44-52.
  10. Omran M. Diseases of the Stomach. Internal M. (Imtz P, ed.). Singapore: McGraw-Hill Professional; 2008.
  11. Lauralee S. Digestive System. In: Human Physiology from Cells to Systems. 6th ed. Singapore: Cengage Learning; 2007.
  12. Pokharkar DV. Stability Indicating RP-HPLC-PDA Method for Simultaneous Determination of Dexketoprofen Trometamol and Paracetamol from tablet dosage form. Der Pharm Lett. 2011;3(6):49-57.
  13. Valles J AR. Clinical pharmacokinetics of parenteral dexketoprofen trometamol in healthy subject. Clin Pharmacol. 2006;A:7-12.
  14. Rahmatsyah. Perbandingan Efek Analgesia Parecoxib dengan Ketorolak Sebagai Preemptif Analgesia pada Anestesi Umum. J Anesthesiol. 2008.
  15. Singh G TG. Appropriate choice of proton pump inhibitor therapy in the prevention and management of NSAID related gastrointestinal damage. Int J Clin Pr. 2005;59:1210-1217.
  16. Scheiman JM CB. Panel discussion: treatment approaches to control gastrointestinal risk and balance cardiovascular risks and benefits: proposals and recommendations. Aliment Pharmacol Ther Symp Ser. 2005;1:26-32.
  17. Valle J. Peptic ulcer disease and related disorders. In: . eds. . 17th ed. New York : In: Fauci AS, Kasper DL, Longo DL, Braunwald E, Hauser SL, Jameson JL LJ, ed. Harrison’s Principle of Internal Medicinie. 17th ed. New York: McGraw-Hill; 2015:1911-1912.
  18. Castellsague J, Holick CN, Hoffman CC, Gimeno V SM and GS. Risk of upper gastrointestinal complications associated with cyclooxygenase-2 selective and nonselective nonstreroidal anti-inflammatory drugs. Pharmacotherapy. 2009;29(12):1397-1407.
  19. Pelletier JM, Lajeunesse D, Reboul P PJ. Therapeutic role of dual inhibitors of 5-LOX and COX selective and nonselective non-steroidal anti-inflammatory drugs. Ann Rheum Dis. 2003;62:501-509.
  20. Lanza FL, Chan FKI QE. Guidelines for prevention of NSAID-related ulcer complication. Am J Gastro. 2009;104:728-738.
  21. Haws MJ, Kucan JO, Roth AC, Suchy H BR. The effects of chronic ketorolac tromethamine (toradol) on wound healing. WR H, ed. BAnn Plast Surg. 1996;37(2):147-151.
  22. Pakneshan P1, Birsner AE, Adini I, Becker CM DR. Differential suppression of vascular permeability and corneal angiogenesis by nonsteroidal anti-inflammatory drugs. Invest Ophthalmol Vis Sci. 2008;49(9):3909-3913.
  23. Scheiman JM. Nonsteroidal anti-inflammatory drug (NSAID)- induced gastropathy. In: KE K, ed. Acute Gastrointestinal Bleeding. Jersey, New: Humana Press; 2003:75-96.
  24. Scheiman JM CB. Panel discussion: treatment approaches to control gastrointestinal risk and balance cardiovascular risks and benefits: proposals and recommendations. Aliment Pharmacol Ther Symp Ser. 2005;1:26-32.
  25. Heriady H AM. Effect Of Parecoxib to Interleukin-6 (Il-6) Serum Concentration and Post Operative Pain Intensity Post Gyneacologic Laparotomy. J Anesthesiol.
  26. Singh G TG. Appropriate choice of proton pump inhibitor therapy in the prevention and management of NSAID related gastrointestinal damage. Int J Clin Pr. 2005;59:1210-1217.
  27. Blandizzi C, Tuccori M, Colucci R, Gori G, Fornai M AL. Clinical efficacy of esomeprazole in the prevention and healing of gastrointestinal toxicity associated with NSAIDs in elderly patients. Drugs Aging. 2008;25:197-208.
  28. Bertouch J SD. Non-steroidal anti-inflammatory drugs. In: N Y, ed. NSAIDs and the Gastrointestinal Track. 2nd ed. Sydney: Sydney NSW 2000; 2008:6-17.
  29. Papatheodoridis GV, Papadelli D, Cholongitas E, Vassilopoulos D, Mentis A HS. Effect of helicobacter pylori infection on the risk of upper gastrointestinal bleeding in users of nonsteroid anti-inflammatory drugs. Am J Med. 2004;116:601-605.
  30. Elnacef N, Scheiman JM, Fendrick AM, Howden CW CW. Changing perceptions and practices regarding aspirin, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs among US primary care providers. Aliment Pharmacol Ther Symp Ser. 2008;28(10):1249-1258.
  31. Brozozowski T, Konturek PC KS. Role of gastric acid secretion in progression of acute gastric erosions induced by ischemia-reperfusion into gastric ulcers. Eurpharmacol. 2000;398:147-158.
  32. Danciu M MM. Chronic Peptic Ulcer. Atlas of Pathology.; 2014.
  33. Brunton L, Parker K, Blumenthal D B. Goodman & Gilman’s Manual of Pharmacology and Therapeutics. New York: McGraw-Hill Professional; 2010.
  34. Warner T. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis. Proc Natl Acad Sci. 1999;96:7563-7568.
  35. Sinha M, Gautam L, Shukla KP, Kaur P, Sharma S ST. Current Perspective in NSAID-Induced Gastropathy. Mediators Inflamm. 2013:1-11.
  36. Yudhowibowo I, Satoto H SH. Obat-obat anti nyeri. J Anesthesiol. 2011.
  37. Koo PJS. Management of acute pain. J Pharm Pract. 2003;16(4):231-248.
  38. Fendrick AM. COX-2 inhibitor use after vioxx: careful balance of end of the rope? Am J Manag Care. 2004;10:740-741.
  39. Barbanoj MJ, Antonijoan RM GI. Clinical pharmacokinetics of dexketoprofen. Clin Pharmacokinet. 2001;40(4):245-262.
  40. Manja B. Pretreatment of Mice with Streptomycin Provides a Salmonella enterica Serovar Typhimurium Colitis Model That Allows Analysis of Both Pathogen and Host. Infect Immunity, Am Soc Microbiol. 2003;71(5):2839-2856.
  41. Mauleon D AR. Preclinical and clinical development of dexketoprofen. Drugs. 1996;52:24-25, 45-46.